W1181 Long-Term Efficacy and Safety of Maintenance Infliximab for the Treatment of Moderate-to-Severe Pediatric Crohn's Disease: Results from the Reach Study
Jeffrey S. Hyams(Connecticut Children's Medical Center), Robert N. Baldassano(Children's Hospital of Philadelphia), Thomas D. Walters(University of Toronto), James Markowitz, George D. Ferry(Baylor College of Medicine), Gigi Veereman, Marion Blank(Janssen (United States)), Anne M. Griffiths(University of Toronto), Harland S. Winter(Philadelphia University), Stanley Cohen(Texas Children's Hospital), Wallace Crandall, Subra Kugathasan(Children's Healthcare of Atlanta), Jewel Johanns(Janssen (United States)), Robert Heuschkel(European CanCer Organisation)
Cited by 2
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k